{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T12:48:18Z","timestamp":1774529298288,"version":"3.50.1"},"reference-count":52,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Anaplastic thyroid carcinoma (ATC) is the most aggressive type of thyroid cancer. Tumor cells have been shown to activate alternative signaling pathways, making treatments less effective. One of the major proteins involved in the progression of ATC is the proto-oncogene KRAS that belongs to a group of small guanosine triphosphate (GTP)-binding proteins. Despite its recognized importance in cancer malignancy, KRAS is considered non-druggable and has never been studied in the field of ATC. In this context, a new synthetic molecule, BAY-293, has recently been developed that selectively inhibits the KRAS\u2013SOS-1 interaction. Based on these findings, the aim of this study was to evaluate for the first time the antitumor effect of BAY-293 using in vitro and in vivo models of ATC. The in vitro model included different thyroid cancer (TC) cell lines used to study the effect of BAY-293 on the modulation of mitogen-activated protein kinase (MAPK) pathways, apoptosis, and cell migration. To confirm the in vitro findings and better mimic the complex tumor microenvironment, an in vivo orthotopic model of ATC was used. The results of the study indicate that BAY-293, both in vitro and in vivo, effectively blocked the KRAS\/MAPK\/ERK pathway and \u03b2-catenin, which act as downstream effectors essential for cell migration, and increased the apoptotic process by slowing the progression of ATC. In conclusion, this study demonstrated that KRAS\/SOS-1 inhibition could be a promising therapeutic target for the treatment of ATC and highlighted BAY-293 as an innovative molecule that needs further research to fully evaluate its efficacy in the field of thyroid cancer.<\/jats:p>","DOI":"10.3390\/ijms26062579","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T06:53:00Z","timestamp":1741848780000},"page":"2579","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["KRAS\u2013SOS-1 Inhibition as New Pharmacological Target to Counteract Anaplastic Thyroid Carcinoma (ATC)"],"prefix":"10.3390","volume":"26","author":[{"given":"Deborah","family":"Mannino","sequence":"first","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D\u2019Alcontres 31, 98166 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossella","family":"Basilotta","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D\u2019Alcontres 31, 98166 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3431-9421","authenticated-orcid":false,"given":"Fabiola","family":"De Luca","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D\u2019Alcontres 31, 98166 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Casili","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D\u2019Alcontres 31, 98166 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2663-6387","authenticated-orcid":false,"given":"Emanuela","family":"Esposito","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D\u2019Alcontres 31, 98166 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Paterniti","sequence":"additional","affiliation":[{"name":"Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D\u2019Alcontres 31, 98166 Messina, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.humpath.2018.07.027","article-title":"Anaplastic thyroid carcinoma: An epidemiologic, histologic, immunohistochemical, and molecular single-institution study","volume":"82","author":"Yang","year":"2018","journal-title":"Human. Pathol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bychkov, A., Agarwal, S., and Keelawat, S. (2024). Anaplastic Thyroid Carcinoma. Thyroid FNA Cytology: Differential Diagnoses and Pitfalls, Springer.","DOI":"10.1007\/978-981-99-6782-7_51"},{"key":"ref_3","first-page":"449","article-title":"Anaplastic thyroid cancer: Multimodal treatment results","volume":"8","author":"Aslan","year":"2014","journal-title":"Ecancermedicalscience"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","article-title":"Overview of the 2022 WHO Classification of Thyroid Neoplasms","volume":"33","author":"Baloch","year":"2022","journal-title":"Endocr. Pathol."},{"key":"ref_5","first-page":"800","article-title":"Anaplastic thyroid cancer: How far can we go?","volume":"19","author":"Amaral","year":"2020","journal-title":"EXCLI J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1089\/thy.2020.0944","article-title":"2021 American thyroid association guidelines for management of patients with anaplastic thyroid cancer: American thyroid association anaplastic thyroid cancer guidelines task force","volume":"31","author":"Bible","year":"2021","journal-title":"Thyroid"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.6004\/jnccn.2022.0040","article-title":"Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Haddad","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_8","first-page":"471","article-title":"Radiation-associated and \u2018spontaneous\u2019 human thyroid carcinomas show a different pattern of ras oncogene mutation","volume":"6","author":"Wright","year":"1991","journal-title":"Oncogene"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1309\/ND8D9LAJTRCTG6QD","article-title":"Molecular profile and clinical-pathologic features of the follicular variant of papillary thyroid carcinoma: An unusually high prevalence of ras mutations","volume":"120","author":"Zhu","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1385\/EP:15:4:319","article-title":"Genetic alterations involved in the transition from well-differentiated to poorly differentiated and anaplastic thyroid carcinomas","volume":"15","author":"Nikiforov","year":"2004","journal-title":"Endocr. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Prete, A., Borges de Souza, P., Censi, S., Muzza, M., Nucci, N., and Sponziello, M. (2020). Update on Fundamental Mechanisms of Thyroid Cancer. Front. Endocrinol., 11.","DOI":"10.3389\/fendo.2020.00102"},{"key":"ref_12","unstructured":"Jeng, H.-H. (2011). Characterization of the Physiological Roles of Sos-WT Ras Signaling Cascade in Oncogenic Ras-Driven Tumorigenesis. [Ph.D. Thesis, New York University]."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"9272","DOI":"10.1039\/D0SC03441J","article-title":"Structural impact of GTP binding on downstream KRAS signaling","volume":"11","author":"Vida","year":"2020","journal-title":"Chem. Sci."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jan\u010d\u00edk, S., Dr\u00e1bek, J., Radzioch, D., and Hajd\u00fach, M. (2010). Clinical relevance of KRAS in human cancers. BioMed Res. Int., 2010.","DOI":"10.1155\/2010\/150960"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: Is the undruggable drugged?","volume":"19","author":"Moore","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.cbpa.2021.02.014","article-title":"Targeting son of sevenless 1: The pacemaker of KRAS","volume":"62","author":"Kessler","year":"2021","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e20201414","DOI":"10.1084\/jem.20201414","article-title":"SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling","volume":"218","author":"Fedele","year":"2021","journal-title":"J. Exp. Med."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Jiang, H., Fan, Y., Wang, X., Wang, J., Yang, H., Fan, W., and Tang, C. (2023). Design, synthesis and biological evaluation of quinazoline SOS1 inhibitors. Bioorg. Med. Chem. Lett., 88.","DOI":"10.1016\/j.bmcl.2023.129265"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12672-022-00550-w","article-title":"Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines","volume":"13","author":"Plangger","year":"2022","journal-title":"Discov. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1038\/s41401-022-00897-4","article-title":"Pan-KRAS inhibitors suppress proliferation through feedback regulation in pancreatic ductal adenocarcinoma","volume":"43","author":"Wang","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Sewell, W., Reeb, A., and Lin, R.Y. (2013). An orthotopic mouse model of anaplastic thyroid carcinoma. J. Vis. Exp., e50097.","DOI":"10.3791\/50097"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1089\/thy.2009.0055","article-title":"A novel orthotopic mouse model of human anaplastic thyroid carcinoma","volume":"19","author":"Nucera","year":"2009","journal-title":"Thyroid"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101230","DOI":"10.1016\/j.tranon.2021.101230","article-title":"Cytotoxicity of combinations of the pan-KRAS inhibitor BAY-293 against primary non-small lung cancer cells","volume":"14","author":"Plangger","year":"2021","journal-title":"Transl. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Kim, H.J., Lee, H.N., Jeong, M.S., and Jang, S.B. (2021). Oncogenic KRAS: Signaling and drug resistance. Cancers, 13.","DOI":"10.3390\/cancers13225599"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Schubert, L., Mariko, M.L., Clerc, J., Huillard, O., and Groussin, L. (2023). MAPK Pathway Inhibitors in Thyroid Cancer: Preclinical and Clinical Data. Cancers, 15.","DOI":"10.3390\/cancers15030710"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41698-018-0049-y","article-title":"Interaction between Wnt\/beta-catenin and RAS-ERK pathways and an anti-cancer strategy via degradations of beta-catenin and RAS by targeting the Wnt\/beta-catenin pathway","volume":"2","author":"Jeong","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"111844","DOI":"10.1016\/j.ejmech.2019.111844","article-title":"Selective apoptosis-inducing activity of synthetic hydrocarbon-stapled SOS1 helix with d-amino acids in H358 cancer cells expressing KRAS(G12C)","volume":"185","author":"Xu","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Piersma, B., Hayward, M.-K., and Weaver, V.M. (2020). Fibrosis and cancer: A strained relationship. Biochim. Biophys. Acta (BBA)-Rev. Cancer, 1873.","DOI":"10.1016\/j.bbcan.2020.188356"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/cncy.22519","article-title":"The American Thyroid Association (ATA) integrates molecular testing into its framework for managing patients with anaplastic thyroid carcinoma (ATC): Update on the 2021 ATA ATC guidelines","volume":"130","author":"Iwata","year":"2022","journal-title":"Cancer Cytopathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1097\/00000478-199906000-00007","article-title":"Downregulation of p27KIP1 and Ki67\/Mib1 labeling index support the classification of thyroid carcinoma into prognostically relevant categories","volume":"23","author":"Tallini","year":"1999","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1245\/ASO.2006.05.042","article-title":"Anaplastic thyroid carcinoma: Biology, pathogenesis, prognostic factors, and treatment approaches","volume":"13","author":"Are","year":"2006","journal-title":"Ann. Surg. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/hed.21721","article-title":"Multimodality therapeutic outcomes in anaplastic thyroid carcinoma: Improved survival in subgroups of patients with localized primary tumors","volume":"34","author":"Ito","year":"2012","journal-title":"Head Neck"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Ljubas, J., Ovesen, T., and Rusan, M. (2019). A systematic review of phase II targeted therapy clinical trials in anaplastic thyroid cancer. Cancers, 11.","DOI":"10.3390\/cancers11070943"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s12022-016-9445-4","article-title":"Genomic landscape of poorly differentiated and anaplastic thyroid carcinoma","volume":"27","author":"Xu","year":"2016","journal-title":"Endocr. Pathol."},{"key":"ref_35","first-page":"159","article-title":"High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis","volume":"4","author":"Lemoine","year":"1989","journal-title":"Oncogene"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1365-2265.1998.00443.x","article-title":"Genetic alterations in human epithelial thyroid tumours","volume":"48","author":"Suarez","year":"1998","journal-title":"Clin. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/BF01957483","article-title":"Detection of the H-RAS oncogene in human thyroid anaplastic carcinomas","volume":"45","author":"Stringer","year":"1989","journal-title":"Experientia"},{"key":"ref_38","first-page":"1997","article-title":"ERK\/MAPK signalling pathway and tumorigenesis","volume":"19","author":"Guo","year":"2020","journal-title":"Exp. Ther. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Ullah, R., Yin, Q., Snell, A.H., and Wan, L. (2022). RAF-MEK-ERK pathway in cancer evolution and treatment. Seminars in Cancer Biology, Academic Press.","DOI":"10.1016\/j.semcancer.2021.05.010"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1517\/14728222.2011.639361","article-title":"The RAS\/RAF\/MEK\/ERK and the PI3K\/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches","volume":"16","author":"Maiello","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/path.4312","article-title":"PTEN loss and KRAS activation leads to the formation of serrated adenomas and metastatic carcinoma in the mouse intestine","volume":"233","author":"Davies","year":"2014","journal-title":"J. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41419-023-06085-4","article-title":"EIF4A3-mediated circ_0042881 activates the RAS pathway via miR-217\/SOS1 axis to facilitate breast cancer progression","volume":"14","author":"Ju","year":"2023","journal-title":"Cell Death Dis."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"115828","DOI":"10.1016\/j.ejmech.2023.115828","article-title":"Inhibition of Son of Sevenless Homologue 1 (SOS1): Promising therapeutic treatment for KRAS-mutant cancers","volume":"261","author":"Chen","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s12931-023-02519-x","article-title":"Prolyl oligopeptidase inhibition ameliorates experimental pulmonary fibrosis both in vivo and in vitro","volume":"24","author":"Cucinotta","year":"2023","journal-title":"Respir. Res."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Cheng, N., Diao, H., Lin, Z., Gao, J., Zhao, Y., Zhang, W., Wang, Q., Lin, J., Zhang, D., and Jin, Y. (2020). Benzyl Isothiocyanate Induces Apoptosis and Inhibits Tumor Growth in Canine Mammary Carcinoma via Downregulation of the Cyclin B1\/Cdk1 Pathway. Front. Vet. Sci., 7.","DOI":"10.3389\/fvets.2020.580530"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1476-4598-1-4","article-title":"Glycerol as a chemical chaperone enhances radiation-induced apoptosis in anaplastic thyroid carcinoma cells","volume":"1","author":"Ohnishi","year":"2002","journal-title":"Mol. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1634\/theoncologist.2010-0317","article-title":"Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer","volume":"16","author":"Nucera","year":"2011","journal-title":"Oncologist"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Fanfone, D., Stanicki, D., Nonclercq, D., Port, M., Vander Elst, L., Laurent, S., Muller, R.N., Saussez, S., and Burtea, C. (2020). Molecular Imaging of Galectin-1 Expression as a Biomarker of Papillary Thyroid Cancer by Using Peptide-Functionalized Imaging Probes. Biology, 9.","DOI":"10.3390\/biology9030053"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Scuderi, S.A., Filippone, A., Basilotta, R., Mannino, D., Casili, G., Capra, A.P., Chisari, G., Colarossi, L., Sava, S., and Campolo, M. (2022). GSK343, an inhibitor of enhancer of zeste homolog 2, reduces glioblastoma progression through inflammatory process modulation: Focus on canonical and non-canonical NF-\u039aB\/I\u03baB\u03b1 Pathways. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232213915"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.semcancer.2020.06.013","article-title":"Primary cell cultures for the personalized therapy in aggressive thyroid cancer of follicular origin","volume":"79","author":"Fallahi","year":"2022","journal-title":"Semin. Cancer Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2579\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:52:55Z","timestamp":1760028775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/6\/2579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ijms26062579"],"URL":"https:\/\/doi.org\/10.3390\/ijms26062579","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,13]]}}}